NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX)
Post# of 231
(Total Views: 224)
Posted On: 09/05/2019 4:14:34 PM
NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Issues Corporate Update; Set to Present at H.C. Wainwright 21st Annual Global Investment Conference
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Tuesday issued an update regarding its clinical development programs, manufacturing and strategy for bringing its Oncoprex(TM) immunogene therapy to market. A corporate presentation is available on GNPX’s website which details anticipated milestones and future guidance for the company. “These milestones emphasize our commitment to developing potentially life-changing gene technologies for cancer patients who need them most,” Genprex chairman and chief executive officer Rodney Varner stated in the news release. “We continue to dedicate our efforts toward developing Oncoprex for non-small cell lung cancer (“NSCLC”) and we believe that achievement of these milestones will enable us to advance our gene therapy platform and position us to bring our drug candidate to commercialization.” In addition, GNPX this morning announced that it will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference in New York City at 3:00 PM ET on Tuesday, September 10, 2019. Genprex chairman and chief executive officer Rodney Varner will lead the presentation and will be available for one-on-one meetings. To set a meeting, contact the company at Investors@Genprex.com.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Tuesday issued an update regarding its clinical development programs, manufacturing and strategy for bringing its Oncoprex(TM) immunogene therapy to market. A corporate presentation is available on GNPX’s website which details anticipated milestones and future guidance for the company. “These milestones emphasize our commitment to developing potentially life-changing gene technologies for cancer patients who need them most,” Genprex chairman and chief executive officer Rodney Varner stated in the news release. “We continue to dedicate our efforts toward developing Oncoprex for non-small cell lung cancer (“NSCLC”) and we believe that achievement of these milestones will enable us to advance our gene therapy platform and position us to bring our drug candidate to commercialization.” In addition, GNPX this morning announced that it will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference in New York City at 3:00 PM ET on Tuesday, September 10, 2019. Genprex chairman and chief executive officer Rodney Varner will lead the presentation and will be available for one-on-one meetings. To set a meeting, contact the company at Investors@Genprex.com.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)